Cigna reported strong Q2 2026 earnings and revenue that beat consensus estimates, and raised its full-year adjusted EPS outlook. However, the company noted a moderation in GLP-1 drug prescription growth, which could impact future revenue streams for its Evernorth Health Services segment.
Cigna's Q2 2026 results showed an earnings and revenue beat, leading to an upward revision of its full-year adjusted EPS guidance. This would typically be a positive catalyst. However, the company's announcement of moderating growth in GLP-1 drug prescriptions, a popular and high-growth area, introduces a significant headwind. This moderation is attributed to declining coverage levels and slowing utilization growth, which could impact the future performance of its Evernorth Health Services, particularly its Pharmacy Benefit Services. While the immediate financial results are strong, the long-term implications of slowing GLP-1 growth could temper investor enthusiasm, as reflected in the stock's initial decline. Traders should monitor how this trend evolves and its potential impact on Cigna's pharmacy benefit management business.